What are vasopressors, their indications, and recommended dosing in adult shock?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 2, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Vasopressors: Comprehensive Overview

What Are Vasopressors?

Vasopressors are medications that raise blood pressure through vasoconstriction by activating specific receptors on vascular smooth muscle. 1 These agents bind to adrenergic receptors (α1, α2, β1, β2), vasopressin receptors (AVPR1a, AVPR1B, AVPR2), angiotensin II receptors (AG1, AG2), and dopamine receptors (DA1, DA2) to induce vasoconstriction and increase systemic vascular resistance. 1

Primary Indications

Septic Shock (Most Common)

  • Administer vasopressors when hypotension persists after a minimum 30 mL/kg crystalloid bolus within the first 3 hours, targeting a mean arterial pressure (MAP) ≥65 mmHg. 2, 3
  • Do not delay vasopressor initiation in severe hypotension (systolic <70 mmHg); start norepinephrine as an emergency measure while fluid resuscitation continues. 2

Other Vasodilatory Shock States

  • Post-cardiotomy shock 3
  • Anaphylaxis refractory to epinephrine and volume resuscitation 2
  • Drug-induced vasodilation 4
  • Post-acute myocardial infarction with vasodilation 4

Limited Role in Other Shock Types

  • Hypovolemic shock: Vasopressors are controversial; volume replacement is the primary treatment. 5
  • Cardiogenic shock: Evidence is limited; norepinephrine may be used cautiously. 5
  • Obstructive shock: Vasopressors temporize blood pressure until definitive therapy addresses the underlying cause. 5

First-Line Agent: Norepinephrine

Why Norepinephrine?

Norepinephrine is the mandatory first-choice vasopressor for septic and vasodilatory shock (Grade 1B recommendation). 3 It reduces 28-day mortality by 11% absolute risk reduction compared to dopamine (NNT = 9), with significantly fewer arrhythmias (53% reduction in supraventricular arrhythmias, 65% reduction in ventricular arrhythmias). 2, 6

Dosing and Administration

  • Starting dose: 0.02–0.05 µg/kg/min (approximately 0.5 mg/h or 8–12 µg/min for a 70 kg adult). 2
  • Standard concentration: Add 4 mg norepinephrine to 250 mL D5W to yield 16 µg/mL. 2
  • Route: Central venous access is strongly preferred to minimize extravasation risk; peripheral IV or intraosseous access may be used temporarily if central access is delayed. 2, 3
  • Titration: Increase by 0.02–0.05 µg/kg/min every 5–10 minutes until MAP ≥65 mmHg is achieved. 2

Hemodynamic Target

  • Standard MAP target: ≥65 mmHg for most patients. 2, 3
  • Chronic hypertension: Target MAP 70–85 mmHg to reduce the need for renal replacement therapy. 2, 3

Monitoring Requirements

  • Arterial catheter placement is recommended for all patients requiring vasopressors to allow continuous blood pressure monitoring. 2, 3
  • Assess tissue perfusion beyond MAP: lactate clearance (repeat within 6 hours if elevated), urine output ≥0.5 mL/kg/h, mental status, capillary refill, and skin perfusion. 2, 3

Second-Line Agent: Vasopressin

When to Add Vasopressin

Add vasopressin at 0.03 units/min (fixed dose) when norepinephrine reaches 0.1–0.25 µg/kg/min and MAP remains <65 mmHg despite adequate fluid resuscitation. 2, 3, 7 Vasopressin provides catecholamine-independent vasoconstriction via V1a receptors, remaining effective when adrenergic receptors are down-regulated in septic shock. 3, 7

Dosing and Safety

  • Standard dose: 0.03 units/min (range 0.01–0.03 units/min). 3, 8
  • Maximum dose: Do not exceed 0.03–0.04 units/min except as salvage therapy; higher doses cause cardiac, digital, and splanchnic ischemia without additional hemodynamic benefit. 2, 3, 8
  • Never use vasopressin as monotherapy; it must always be combined with norepinephrine. 3, 7, 8

FDA-Approved Dosing by Indication

  • Septic shock: 0.01–0.07 units/min. 8
  • Post-cardiotomy shock: 0.03–0.1 units/min. 8

Third-Line Agent: Epinephrine

When to Add Epinephrine

Add epinephrine starting at 0.05 µg/kg/min (titrate up to 0.3 µg/kg/min) when MAP cannot be achieved with norepinephrine plus vasopressin. 2, 3 Epinephrine is an alternative to vasopressin when additional vasopressor support is needed. 3

Important Caveats

  • Epinephrine increases myocardial oxygen consumption more than norepinephrine and causes transient lactic acidosis through β2-adrenergic stimulation of skeletal muscle, interfering with lactate clearance as a resuscitation endpoint. 3
  • Higher risk of serious cardiac arrhythmias, particularly when combined with norepinephrine. 3

Inotropic Support: Dobutamine

When to Add Dobutamine

Add dobutamine 2.5–20 µg/kg/min when MAP is adequate (≥65 mmHg) but signs of tissue hypoperfusion persist (elevated lactate, low urine output, altered mental status, cold extremities), especially if myocardial dysfunction is evident. 2, 3

Mechanism

Dobutamine improves cardiac output via β1-adrenergic stimulation while raising heart rate; it is superior to dopamine for low-output states. 3

Titration

Start at 2.5 µg/kg/min and double the dose every 15 minutes according to response; dose titration is usually limited by excessive tachycardia, arrhythmias, or ischemia. 3

Agents to Avoid

Dopamine

Dopamine is strongly contraindicated as first-line therapy (Grade 1A recommendation). 2, 3 It is associated with an 11% absolute increase in mortality and significantly more supraventricular (RR 0.47) and ventricular arrhythmias (RR 0.35) compared to norepinephrine. 2, 6

  • Only acceptable indication: Highly selected patients with absolute or relative bradycardia and low arrhythmia risk. 3
  • Low-dose dopamine for renal protection is strongly contraindicated (Grade 1A); it provides no benefit and delays appropriate therapy. 2, 3

Phenylephrine

Phenylephrine is not recommended as first-line therapy because it may raise blood pressure while worsening tissue perfusion through pure α-agonist vasoconstriction and reflex bradycardia. 2, 3, 9

  • Only acceptable indications: (1) norepinephrine-induced serious arrhythmias, (2) documented high cardiac output with persistent hypotension, or (3) salvage therapy after failure of all other agents. 2, 3
  • FDA-approved dosing for septic shock: 0.5–6 µg/kg/min by continuous IV infusion; doses above 6 µg/kg/min show no significant incremental increase in blood pressure. 9

Practical Escalation Algorithm

  1. After 30 mL/kg crystalloid bolus, if MAP <65 mmHg, start norepinephrine 0.02–0.05 µg/kg/min. 2, 3
  2. Titrate norepinephrine to MAP ≥65 mmHg (or 70–85 mmHg in chronic hypertension). 2, 3
  3. When norepinephrine reaches 0.1–0.25 µg/kg/min and MAP remains <65 mmHg, add vasopressin 0.03 units/min (fixed dose). 2, 3, 7
  4. If MAP is still inadequate, add epinephrine 0.05 µg/kg/min, titrating up to 0.3 µg/kg/min. 2, 3
  5. If MAP is adequate but hypoperfusion persists, add dobutamine 2.5–20 µg/kg/min to improve cardiac output. 2, 3
  6. For refractory shock after ≥4 hours of high-dose vasopressors, consider hydrocortisone 200 mg/day IV. 2, 3

Vasopressor Weaning Strategy

Preconditions for Weaning

  • Confirm sustained MAP ≥65 mmHg for at least 2 hours without dose escalation. 7
  • Verify adequate tissue perfusion: lactate clearance, urine output ≥0.5 mL/kg/h, improving mental status, warm extremities with brisk capillary refill. 7

Weaning Sequence

Wean norepinephrine first and discontinue vasopressin last. 7 Withdrawing vasopressin before norepinephrine leads to greater hemodynamic instability, as demonstrated in the VASST and VANISH trials. 7

  • Reduce norepinephrine gradually by 0.01–0.02 µg/kg/min every 15–30 minutes while maintaining vasopressin at 0.03 units/min. 7
  • Discontinue vasopressin abruptly once norepinephrine has been tapered to low doses (<0.1 µg/kg/min) and hemodynamics remain stable. 7

Critical Pitfalls to Avoid

  • Do not delay norepinephrine while pursuing excessive fluid resuscitation in profound hypotension (systolic <70 mmHg). 2
  • Do not focus solely on MAP; incorporate tissue-perfusion markers (lactate, urine output, mental status) into decision-making. 2, 3
  • Do not exceed vasopressin dosing beyond 0.03–0.04 units/min to avoid end-organ ischemia. 2, 3, 8
  • Do not use dopamine for renal protection; it is contraindicated and delays appropriate therapy. 2, 3
  • Do not combine dopamine with epinephrine due to additive adverse effects. 3
  • Do not use phenylephrine as first-line therapy; it can raise systemic pressure while impairing microcirculatory flow and renal perfusion. 2, 3

Special Considerations

Extravasation Management

  • If extravasation occurs, infiltrate phentolamine 5–10 mg diluted in 10–15 mL saline intradermally at the site immediately to prevent tissue necrosis. 2
  • Pediatric dose: 0.1–0.2 mg/kg up to 10 mg. 2

Pediatric Dosing

  • Norepinephrine: 0.1–1.0 µg/kg/min, starting at the lowest dose; maximum doses up to 5 µg/kg/min may be necessary. 2
  • Vasopressin: 0.0002–0.002 units/kg/min for vasodilatory shock. 2

Pregnancy

  • Vasopressin may induce uterine contractions. 8
  • Consider more restrictive initial fluid boluses (1–2 L) due to lower colloid oncotic pressure and higher pulmonary edema risk. 2

References

2
Guideline

Norepinephrine Drip Administration Protocol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Vasopressor Management in Septic Shock

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

4
Research

Vasopressor Therapy in the Intensive Care Unit.

Seminars in respiratory and critical care medicine, 2021

5
Research

A Clinical Review of Vasopressors in Emergency Medicine.

The Journal of emergency medicine, 2024

7
Guideline

Norepinephrine Tapering and Vasopressin Addition Protocol

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the indications for vasopressor (vasopressin) therapy?
What are the mechanisms and indications for all vasopressors, including norepinephrine (NE), epinephrine (EPI), dopamine (DA), phenylephrine (PE), and vasopressin (VP)?
What is the preferred vasopressor (medication to constrict blood vessels) or inotrope (medication to increase heart contractility) for treating hypotension (low blood pressure), comparing dobutamine, dopamine, and norepinephrine?
At what dose of norepinephrine and vasopressin should a third vasopressor be used?
How should I manage a 45-year-old male with uncontrolled hypertension and diabetes, four days post‑major abdominal surgery, who is confused, cold, pale, with a mean arterial pressure of 45 mm Hg, central venous pressure of 8 cm H₂O, and oliguria after fluid resuscitation?
What is the appropriate emergency management for a patient with constant chest pain for the past two hours?
What is the most appropriate next step in managing a patient with bilateral hand eczema who did not improve after a recent corticosteroid injection?
Is there an LDL (low-density lipoprotein) cholesterol threshold that warrants starting statin (HMG‑CoA reductase inhibitor) therapy even when HDL (high-density lipoprotein) cholesterol is very high (e.g., LDL 7 mmol/L and HDL 3 mmol/L)?
In a patient with confirmed gonorrhea infection presenting with lower abdominal pain, what is the most likely diagnosis and is acute pyelonephritis likely?
Is the vas deferens the first structure ligated during a radical orchiectomy?
How is a specific learning disorder diagnosed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question